Coeptis Therapeutics (NASDAQ:COEP) Shares Down 6.7% – Should You Sell?

Shares of Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) were down 6.7% during trading on Monday . The company traded as low as $6.91 and last traded at $7.05. Approximately 47,666 shares changed hands during mid-day trading, a decline of 60% from the average daily volume of 118,326 shares. The stock had previously closed at $7.56.

Analyst Ratings Changes

Separately, Wall Street Zen upgraded Coeptis Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, May 22nd.

Coeptis Therapeutics Stock Performance

The stock has a fifty day moving average price of $9.23 and a two-hundred day moving average price of $8.98. The company has a market cap of $24.75 million, a P/E ratio of -1.22 and a beta of -0.59. The company has a debt-to-equity ratio of 0.02, a current ratio of 0.82 and a quick ratio of 0.82.

Coeptis Therapeutics (NASDAQ:COEP) last announced its earnings results on Wednesday, May 14th. The company reported ($1.11) EPS for the quarter.

Coeptis Therapeutics Company Profile

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.